|Articles|January 19, 2021
Screening developability and pre-formulation by HT-DLS
Author(s)Wyatt Technology
Assessing a drug candidate early in discovery and development minimizes the risk of costly downstream failure. This white paper illustrates the application of automated DLS for aggregation and stability investigations.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Related Content
Trending on BioPharm International
1
A Scientifically Justified Agitation Stress Model for Early-Stage Biologics
2
Mastering Phase-Appropriate Characterization for Biologics Approval
3
Transforming Clinical Bioanalysis for Manufacturing Scalability
4
From Lab to Patient: The Critical Role of Supply Chain & Distribution in the Life Sciences
5
